| Income Statement | 2025-09-30 | 2025-06-30 | ||
|---|---|---|---|---|
| Research and development | 504,387 | 617,835 | ||
| General and administrative | - | 1,154,896 | ||
| Selling, general and administrative (including related party amounts of 334,050, 0, 334,050, and 0, respectively) | 1,256,284 | - | ||
| Total operating expenses | 1,760,671 | 1,772,731 | ||
| Loss from operations | -1,760,671 | -1,772,731 | ||
| Interest income | 68,682 | 71,638 | ||
| Net loss | -1,691,989 | -1,701,093 | ||
| Net loss per share of common stock, basic | -1.65 | -1.66 | ||
| Net loss per share of common stock, diluted | -1.65 | -1.66 | ||
| Weighted-average basic common stock | 1,026,457 | 1,026,506 | ||
| Weighted-average diluted common stock | 1,026,457 | 1,026,506 | ||
Dermata Therapeutics, Inc. (DRMA)
Dermata Therapeutics, Inc. (DRMA)